BioSpace News Archive

Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved Taltz® injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.

Business Provides Hospice Services through 21 Locations Across Six States, Producing Annualized Revenue of Approximately $55 Million

Lock-up includes founders, early shareholders and other key stakeholders and represents approximately 47% of outstanding shares (common equivalents)

Prancer RTSM Selected for Innovation in Cohort Management for Highly Complex Trials

The Medicines Company announced positive topline results from the first pivotal Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing.

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Wells Fargo Healthcare Conference in Boston, MA.

Masimo announced that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ could reduce the time critically ill patients spend with moderate hyperoxia, compared to monitoring with oxygen saturation alone.

The Australian Government invests $40 million to provide patients affordable access to two new medicine listings through the Pharmaceutical Benefit Scheme (PBS)